Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKesson
Cerilliant
Novartis
Fish and Richardson
Boehringer Ingelheim
Federal Trade Commission
Daiichi Sankyo
US Department of Justice

Generated: December 11, 2017

DrugPatentWatch Database Preview

OCTREOSCAN Drug Profile

« Back to Dashboard

When do Octreoscan patents expire, and what generic alternatives are available?

Octreoscan is a drug marketed by Mallinkrodt Nuclear and is included in one NDA. There is one patent protecting this drug.

This drug has twelve patent family members in eight countries.

The generic ingredient in OCTREOSCAN is indium in-111 pentetreotide kit. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetreotide kit profile page.

Summary for OCTREOSCAN

Drug patent expirations by year for OCTREOSCAN

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt NuclearOCTREOSCANindium in-111 pentetreotide kitINJECTABLE;INJECTION020314-001Jun 2, 1994RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OCTREOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt NuclearOCTREOSCANindium in-111 pentetreotide kitINJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt NuclearOCTREOSCANindium in-111 pentetreotide kitINJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt NuclearOCTREOSCANindium in-111 pentetreotide kitINJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt NuclearOCTREOSCANindium in-111 pentetreotide kitINJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OCTREOSCAN

Country Document Number Estimated Expiration
United Kingdom2241167► Subscribe
Hong Kong43497► Subscribe
Italy1244496► Subscribe
Japan3288055► Subscribe
Germany4104308► Subscribe
JapanH05124979► Subscribe
ItalyRM910115► Subscribe
United Kingdom9103344► Subscribe
Switzerland683318► Subscribe
Belgium1004645► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
Farmers Insurance
Argus Health
Fish and Richardson
McKinsey
Harvard Business School
AstraZeneca
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot